Drone temperature-controlled medicine delivery programme test completed
16 July 2019 | By European Pharmaceutical Review
The successful pilot programme could represent an important step forward in biopharmaceutical supply chain innovation.
List view / Grid view
Vaccines
Suspected counterfeit vaccines seized in Hong Kong
15 July 2019 | By Victoria Rees (European Pharmaceutical Review)
A medical centre in Hong Kong had 76 boxes of an HPV vaccine seized after a complaint from a patient who experienced adverse side effects.
Whitepaper: Impact of the Claristep® Filtration System on recovery and adsorption of various therapeutic proteins at low sample volumes
10 July 2019 | By Sartorius
Comparison of the Sartorius Claristep Filtration System with standard sample preparation using syringe filters.
Report suggests process for vaccine trials during health crises
3 July 2019 | By Victoria Rees (European Pharmaceutical Review)
A recent report has presented an argument for updating vaccine development during health emergencies to increase efficiency.
Job cuts limit cardiovascular and diabetes research and development
25 June 2019 | By European Pharmaceutical Review
Pharmaceutical company, Sanofi, will eliminate jobs in France and Germany and end new in-house cardiology research programmes.
Rabies vaccines shortage puts Delhi on brink of crisis
10 June 2019 | By Victoria Rees (European Pharmaceutical Review)
Decreased supply of anti-rabies vaccines (ARVs) in Delhi causes outbreak of the disease.
Influenza A vaccine enters Phase IIb trial
5 June 2019 | By Victoria Rees (European Pharmaceutical Review)
Novel influenza A vaccine has been administered to first patients in Phase IIb trial.
Single vaccination approach developed to combat respiratory diseases
23 May 2019 | By European Pharmaceutical Review
Scientists have developed a single vaccination approach to simultaneously combat influenza and pneumococcal infections.
Tuberculosis: fighting the disease with a single vial
13 May 2019 | By Christopher Fox, Dr Daniel Hoft
Vaccinations have begun in a phase I human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis vaccine candidate. Nikki Withers speaks to Dr Daniel Hoft and Christopher Fox about the formulation process and what this means for vaccine development going forward.
Novel colorectal cancer vaccine shows positive phase I results
2 May 2019 | By European Pharmaceutical Review
A new vaccine for colorectal cancer has proven to be safe in a small sample of human subjects, opening the way for the next phase of testing.
$100 million is to be invested to increase vaccine manufacturing in US
30 April 2019 | By European Pharmaceutical Review
A $100 million investment has been made to support long-term vaccine manufacturing capabilities in the US.
Guide To Testing
26 April 2019 | By European Pharmaceutical Review
In this edition of our ‘Guide to’ series, learn how these leading companies’ services and expertise can help you test your pharma/ biopharma products and medical devices.
Formulation In-Depth Focus 2019
26 April 2019 | By European Pharmaceutical Review
As today’s scientists continue to identify new biopharmaceutical products with potential to treat a wide array of diseases, formulation remains the determining factor in their success. But what is involved in these increasingly complex formulation processes and how do they impact the packaging and delivery systems?
European Pharmaceutical Review Issue 2 2019
25 April 2019 | By European Pharmaceutical Review
This issue questions whether companies are sufficiently investing in regulatory intelligence software and what the potential consequences of Brexit might be for locations outside of the UK and EU. The issue also features articles on microbiology, formulation and biopharma, courtesy of our in-depth focus sections; as well as outlining the…
Landmark Malaria vaccine pilot programme launched in Malawi
25 April 2019 | By European Pharmaceutical Review
The Government of Malawi has launched the world’s first malaria vaccine which will be made available to children up to two years of age.
Follow: